Intranasal sumatriptan effective in adolescents with migraine

    loading  Checking for direct PDF access through Ovid


Intranasal sumatriptan is effective and generally well tolerated in the treatment of acute migraine in adolescent patients, according to the results from a study presented at the 56th Annual Meeting of the American Academy of Neurology (AAN) [San Francisco, US; April−May 2004].1 A total of 738 patients aged 12−17 years were involved in the randomised, double-blind, placebo-controlled study. The probability of achieving a headache response was significantly greater with sumatriptan 20mg nasal spray than with placebo at 30 minutes, 1 hour and 2 hours postdose. The most frequently reported adverse event was taste disturbance. These results are consistent with previous results from a similar study conducted in US adolescents. Currently, none of the triptan class of headache medications has received US FDA approval for the treatment of migraine in adolescent patients.

    loading  Loading Related Articles